Pharmaceutical

AbbVie and FutureGen link on inflammatory bowel disease

AbbVie has made a licence agreement with FutureGen Biopharmaceutical for developing FG-M701 for inflammatory bowel disease (IBD).

Jun 16, 2024 - 04:00
AbbVie and FutureGen link on inflammatory bowel disease
AbbVie has made a licence agreement with FutureGen Biopharmaceutical for developing FG-M701 for inflammatory bowel disease (IBD).
Read the original article

Tags:

Previous Article

Suven Pharmaceuticals to gain controlling stake in Sapala Organics

Next Article

UK’s new Netflix-style funding model for antibiotics goes live

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Leading innovators in zinc-finger nucleases for the pharmaceutical industry

Leading innovators in zinc-finger nucleases for the pha...

May 8, 2023

STAT+: AbbVie purchases neuroscience developer Cerevel for $8.7 billion

STAT+: AbbVie purchases neuroscience developer Cerevel ...

Dec 7, 2023

Opinion: Dental care is in crisis. But it’s also a moment of opportunity

Opinion: Dental care is in crisis. But it’s also a mome...

Feb 13, 2024